N/A N=184 Basic Science

Oscillatory Contributions to Working Memory and Attention

Young Adults

Bottom Line

View on ClinicalTrials.gov: NCT03787134 ↗

Enrolled (actual)

184

Serious AEs

0.0%

Results posted

Oct 2024

Primary outcome: Primary: Behavioral Accuracy: Sub-study 1 — 86.3; 87.1 percentage of correct responses

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: working memory and attention (Behavioral)
Age: Adult · 18+ yrs
Sex: All
Sponsor: University of Wisconsin, Madison
Primary completion: Apr 2023

Outcome Measures

Outcome	Result	p-value
PRIMARY Behavioral Accuracy: Sub-study 1	86.3; 87.1	—
PRIMARY Behavioral Accuracy: Sub-study 2	85.7; 78.5	—
PRIMARY Behavioral Accuracy: Sub-study 3	72; 67	—
PRIMARY Behavioral Accuracy: Sub-study 5	86.5; 86	—
PRIMARY Behavioral Accuracy: Sub-study 7	11.96; 13.12	—
PRIMARY Reaction Time: Sub-study 1	811; 823	—
PRIMARY Reaction Time: Sub-study 2	850; 660	—
PRIMARY Reaction Time: Sub-study 3	1004; 1070	—
PRIMARY Reaction Time: Sub-study 5	970; 990	—
PRIMARY Reaction Time: Sub-study 6	750; 675	—
PRIMARY Multivariate Pattern Classification of EEG Data: Sub-study 1	.55; .54; .52; .49	—
PRIMARY Multivariate Inverted Encoding Modeling (IEM) Reconstruction: Sub-study 2	-0.0108; 0.0033	.335
PRIMARY Transcranial Magnetic Stimulation (TMS) Effects on EEG Data Component Strengths: Sub-study 1	4.57; 4.5; 40.12; 40.45; 46.33; 45.5	—
PRIMARY Alpha Band Power as a Function of Location Relevance in Working Memory: Sub-study 3	6.16; 6.19; 6.2; 5.83; 6.05; 6.02	—
PRIMARY The Amplitude of Contralateral Delay Activity (CDA): Sub-study 4	.25; .2	—
PRIMARY The Amplitude of the "Contralateral Delay Activity" (CDA): Sub-study 6	.6; .75	—
PRIMARY Experiment 2.a. The Amplitude of Multivariate Inverted Encoding Model-reconstructions of Stimulus Location, Derived From the Transcranial Magnetic Stimulation-evoked Response	—	—
PRIMARY Experiment 2.a. Spatially Distributed Phase Coupling Extraction-identified Components of the Transcranial Magnetic Stimulation-evoked Electroencephalography Signal	—	—
PRIMARY Experiment 2.a. Correlation of the Amplitude of Multivariate Inverted Encoding Model-reconstructions of the Location of the Unattended Memory Item With Alpha Band Power.	—	—
PRIMARY Experiment 2.a. Correlation of the Amplitude of Multivariate Inverted Encoding Model-reconstructions of the Location of the Unattended Memory Item With Beta-band Power	—	—
PRIMARY Experiment 3.a. Frequency in the Alpha Band of the EEG as a Function of Retinotopic Location	—	—
PRIMARY Experiment 3.a. Spatially Distributed Phase Coupling Extraction-identified Components of the Electroencephalography Signal From Signals Corresponding to the Attended Location	—	—
PRIMARY Experiment 4.a. Reaction Time Assess as Latency to Press Response Button After Onset of Critical Stimulus.	—	—
PRIMARY Experiment 4.a. Power in the Alpha Band of the EEG as a Function of Retinotopic Location	—	—
PRIMARY Experiment 4.a. Frequency in the Alpha Band of the EEG as a Function of Retinotopic Location	—	—
PRIMARY Experiment 4.a. Spatially Distributed Phase Coupling Extraction-identified Alpha-band Components of the Electroencephalography Signal From Signals Corresponding to the Attended Location	—	—
PRIMARY Experiment 6. Multivariate Inverted Encoding Modeling of the EEG Signal to Determine Whether or Not Contextual Information is Carried in This Signal	—	—

Summary

The objectives are articulated in the proposal's specific aims: Aim 1: To test the hypothesis that the cognitive control of unattended memory items (UMI) is implemented by the same frontoparietal mechanisms that control spatial and nonspatial attention. Aim 2: To test the hypothesis that the selection of visual stimuli, whether from the environment or from WM, is accomplished, in part, by the hijacking of low-frequency oscillatory dynamics that are fundamental to the waking-state physiology of the corticothalamic circuitry of the visual system. Aim 3: To test the hypothesis that the function of context binding contributes to delay-period activity of the posterior parietal cortex (PPC).

Eligibility Criteria

Inclusion Criteria

Age of # 18 <36. - Right-handed.
Be in good health determined by the investigator on basis of medical history, physical and neurological exam; for "EEG-only" sessions no physical or neurological exams will be performed;
Female subjects must be two years past menopause, surgically sterile or practicing a medically acceptable method of birth control (does not apply to "EEG-only" sessions);
Female subjects must not be pregnant.
Able to understand and speak English.
Able to provide written consent prior to admission

Exclusion Criteria

History of epilepsy, stroke, brain surgery, cranial metal implants, structural brain lesion, devices that may be affected by TMS or tCS(pacemaker, medication pump, cochlear implant, implanted brain stimulator); - Women who are breast-feeding (self report)*;
History of head trauma with loss of consciousness for greater than 5 minutes;
Any history of seizures;
Any family history of seizures*;
Diabetes requiring insulin treatment*;
A serious heart disorder or subjects who have had a heart attack within the last 3 months;
Subjects who meet DSM-IV criteria for alcohol /drug abuse problems within the last six months;
Any current Axis I or II diagnoses or past Axis I diagnoses;
Required use of medication that affects CNS function;
A subject with metallic implants, such as prostheses, shrapnel or aneurysm clip-S, or persons with electronic implants, such as cardiac pacemakers. The magnetic field generated by the MR machine can cause a displacement or malfunctioning of these devices*;
The female subject who is pregnant or planning to become pregnant; or a female subject of child-bearing potential who is not practicing a medically acceptable form of birth control*;
The subject has had a diagnosis of cancer in the past 3 years and/or has active neoplastic disease;
The investigator anticipates that the subject will be unable to comply with the protocol.
Prohibited Concomitant Treatment: Any investigational medication; antipsychotic, antidepressant; or ECT; Other psychotropic medications including sedative hypnotics (excluding chloral hydrate zaleplon); sumatriptan (and similar agents); anxiolytics and herbals (e.g., St. John's Wort, Kava Kava); an introduction or change in intensity of psychotherapy; any nonpsychopharmacologic drug with psychotropic effects (e.g., antihistamines, beta blockers).
Colorblindness
Poor or Uncorrected Vision
History of fainting/syncope

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03787134). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.